持续输注低剂量碘海醇可测量危重患者肾小球滤过率的变化
该临床观察性探索研究在成人ICU中纳入三组患者:肾切除组(n=10)、手术组(n=11)和急性肾损伤组(n=13),持续输注低剂量碘海醇24–80小时,定时测量血浆(ClP)和肾脏(ClR)碘海醇清除率。22例患者满足肾脏病:改善全球结局急性肾损伤标准(肾切除=5、手术=4、急性肾损伤=13),而持续输注低剂量碘海醇显示29例存在急性肾损伤(肾切除=10、手术=8、急性肾损伤=11)。所有患者的肾小球滤过率动态变化均被追踪;肾切除组ClR如预期下降50%(50.8%±11.0%)。ClP与ClR的一致性随输注时间延长而改善:48小时时ClP对ClR的偏倚为-0.1±3.6 mL/min/1.73 m(一致性界限:-7.2至7.1 mL/min/1.73 m),实验室样本分析变异系数为2.4%。作者认为持续输注低剂量碘海醇可能为测试急性肾损伤诊断新型生物标志物提供有用标准。
要点
- 持续输注低剂量碘海醇24–80小时,可在危重患者中追踪肾小球滤过率的动态变化。
- 22例满足肾脏病:改善全球结局急性肾损伤标准,而持续输注低剂量碘海醇显示29例存在急性肾损伤。
- 肾切除组ClR如预期下降50%(50.8%±11.0%)。
- 48小时时ClP对ClR的偏倚为-0.1±3.6 mL/min/1.73 m,一致性界限-7.2至7.1 mL/min/1.73 m。
- 实验室样本分析变异系数为2.4%。
适用人群与场景
- 成人ICU患者,分为三组:肾切除组(急性肾损伤发生和结局可预测,n=10)、手术组(急性肾损伤发生可预测、结局不可预测,n=11)、急性肾损伤组(急性肾损伤发生和结局均不可预测,n=13)。
诊断标准与关键阈值
- 肾脏病:改善全球结局急性肾损伤标准:22例患者满足(肾切除=5、手术=4、急性肾损伤=13)。
- 持续输注低剂量碘海醇显示急性肾损伤:29例患者(肾切除=10、手术=8、急性肾损伤=11)。
- 原文提出:危重患者中肾小球滤过率变化大于10.3%提示急性肾损伤。
处置流程与药物剂量
- 持续输注低剂量碘海醇24–80小时,定时测量血浆(ClP)和肾脏(ClR)碘海醇清除率。
研究设计与关键结果
- 临床观察性探索研究,成人ICU,三组共34例患者(肾切除组n=10、手术组n=11、急性肾损伤组n=13)。
- 22例满足肾脏病:改善全球结局急性肾损伤标准(肾切除=5、手术=4、急性肾损伤=13);持续输注低剂量碘海醇显示29例存在急性肾损伤(肾切除=10、手术=8、急性肾损伤=11)。
- 所有患者的肾小球滤过率动态变化均被追踪。
- 肾切除组ClR如预期下降50%(50.8%±11.0%)。
- ClP与ClR的一致性随输注时间延长而改善:48小时时ClP对ClR的偏倚为-0.1±3.6 mL/min/1.73 m(一致性界限:-7.2至7.1 mL/min/1.73 m)。
- 实验室样本分析变异系数为2.4%。
证据类型、等级与局限
- 证据类型:临床观察性探索研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为持续输注低剂量碘海醇在测量肾小球滤过率时准确且精确,并能追踪不同急性肾损伤风险患者的变化。
- 作者认为持续输注低剂量碘海醇可能为测试急性肾损伤诊断新型生物标志物提供有用标准。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Measurement of changing glomerular filtration rate in acute kidney injury remains problematic. We have previously used a continuous infusion of low-dose Iohexol to measure glomerular filtration rate in stable subjects and postulate that changes greater than 10.3% in critically ill patients indicate acute kidney injury. Our objective is to explore the extent to which continuous infusion of low-dose Iohexol can be a measure of changing glomerular filtration rate during acute kidney injury.
DESIGN: Clinical observational exploratory study.
PATIENTS: Three patient groups were recruited: nephrectomy group: predictable onset of acute kidney injury and outcome (n = 10); surgery group: predictable onset of acute kidney injury, unpredictable outcome (n = 11); and acute kidney injury group: unpredictable onset of acute kidney injury and outcome (n = 13).
INTERVENTIONS: Continuous infusion of low-dose Iohexol was administered for 24-80 hours. Plasma (ClP) and renal (ClR) Iohexol clearances were measured at timed intervals.
MEASUREMENTS AND MAIN RESULTS: Kidney Disease: Improved Global Outcomes acute kidney injury criteria were fulfilled in 22 patients (nephrectomy = 5, surgery = 4, and acute kidney injury = 13); continuous infusion of low-dose Iohexol demonstrated acute kidney injury in 29 patients (nephrectomy = 10, surgery = 8, acute kidney injury = 11). Dynamic changes in glomerular filtration rate were tracked in all patients. In the nephrectomy group, ClR decreased by an expected 50% (50.8% ± 11.0%). Agreement between ClP and ClR improved with increasing duration of infusion: bias of ClP versus ClR at 48 hours was -0.1 ± 3.6 mL/min/1.73 m (limits of agreement: -7.2 to 7.1 mL/min/1.73 m). Coefficient of variation of laboratory sample analysis was 2.4%.
CONCLUSIONS: Continuous infusion of low-dose Iohexol is accurate and precise when measuring glomerular filtration rate and tracks changes in patients with differing risks of acute kidney injury. Continuous infusion of low-dose Iohexol may provide a useful standard against which to test novel biomarkers for the diagnosis of acute kidney injury.
参考来源
- Dixon JJ, Lane K, Dalton RN, et al. Continuous Infusion of Low-Dose Iohexol Measures Changing Glomerular Filtration Rate in Critically Ill Patients. Crit Care Med. 2018. PMID: 29194145. doi:10.1097/CCM.0000000000002870
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。